Trendlines-backed AquiNovo signs deal with Neovia for US$1.5m
AQUINOVO, a company backed by Catalist-listed medical technology incubator The Trendlines Group (Trendlines), has signed an agreement with animal nutrition and health company Neovia for an aggregate investment of US$1.5 million.
Israel-based AquiNovo develops solutions to improve farmed fish development to meet the evergrowing demand for fish protein.
AquiNovo's technology addresses this growing demand with a non-genetically modified organism, non-hormonal, easy-to-use solution for accelerating farmed fish growth, the company said in a statement.
Its CEO Nissim Chen said: "This strategic investment from Neovia affirms their confidence in the company, its vision and its achievements to date. We're excited to work with Neovia on the development of innovative solutions for the aquaculture market."
Steve Rhodes, chairman and CEO of Trendlines, added: "AquiNovo's technology can make a significant contribution to the rapidly growing aquaculture industry and its evolving challenges."
This latest investment comes less than two weeks after Trendlines announced a memorandum of understanding with National Healthcare Group (NHG) to co-develop healthcare solutions for unmet clinical needs - its first collaboration with a healthcare institution in Singapore.
Trendlines shares finished S$0.002 or 1.4 per cent up at S$0.145 on Monday.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Companies & Markets
Hong Kong regulator to probe PwC auditing role over Evergrande
US: S&P, Dow open flat as Middle East jitters ease, Netflix weighs on Nasdaq
DBS puts 46 retail units, HDB shops on market for S$210 million
China to facilitate Hong Kong IPOs and expand Stock Connect
Global equity funds see surge in outflows as rate cut hopes fade
Gazelle Ventures makes cash offer for No Signboard shares at S$0.0021 apiece